Radiopharmaceutical firm Diatide reported last month that it received an expected $2 million milestone payment from marketing partner Nycomed Amersham. The payment is in response to Diatide's filing of new drug application (NDA) for NeoTect, a lung
Radiopharmaceutical firm Diatide reported last month that it received an expected $2 million milestone payment from marketing partner Nycomed Amersham. The payment is in response to Diatide's filing of new drug application (NDA) for NeoTect, a lung cancer imaging agent formerly called P829.
Nycomed's payment comes only weeks after the Buckinghamshire, U.K., firm announced that it would terminate an option and development agreement with Diatide for some products (SCAN 8/19/98). At the time of the announcement, both firms emphasized that Nycomed's withdrawal would not affect its marketing of NeoTect or AcuTect, Diatide's technetium-labeled agent for the detection and localization of acute venous thrombosis. The FDA could clear AcuTect this month, according to Diatide executives.
The Londonderry, NH, firm submitted its NeoTect NDA in June and has received a six-month priority classification from the Food and Drug Administration. The company expects NeoTect to be approved by the end of the year. Nycomed will pay Diatide another $2 million when the agent is approved.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.